Why the study?
Does a benazepril-amlodipine combination improve fibrinolysis compared to monotherapy in hypertensive type 2 diabetic patients?
Does a benazepril-amlodipine combination improve fibrinolysis compared to monotherapy in hypertensive type 2 diabetic patients?
The combination of benazepril and amlodipine improves fibrinolytic balance more than either monotherapy in hypertensive patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports preferring ACEI-CCB combinations in hypertensive T2DM; extends RCT evidence on additive fibrinolytic effects.
The aim of this study was to evaluate the effect of benazepril-amlodipine combination on plasma tissue plasminogen activator (t-PA) and inhibitor 1 (PAI-1) activity in hypertensive type 2 diabetic patients. After a 4 week placebo run-in period 30 hypertensive patients (DBP ≥ 95 ≤ 105 mmHg) with well controlled type 2 diabetes were randomized to benazepril 10 mg or amlodipine 5 mg or benazepril amlodipine combination according to a 3x3 cross over design; each treatment had a 4 week duration. The last day of the placebo run-in period and of each treatment period blood pressure was measured and a venous blood sample was taken (at the same hour in the morning) to evaluate plasma PAI-1 and t-PA activity. The results are shown in the table. These results suggest that in patients with impaired fibrinolysis an ACE inhibitor-Ca blocker combination improve the fibrinolysic balance more than the single monotherapies. It represents a further indication to the use of ACE inhibitor-Ca blocker combination in diabetic hypertensive patients, where it is difficult to reach the required blood pressure target with a single drug. Main Results P < 0.05; p < 0.01; p < 0.001 Main Results P < 0.05; p < 0.01; p < 0.001
No takes yet. Share an insight, caveat, or question.
Roberto Fogari (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: